The Zacks Analyst Blog Highlights: Krispy Kreme Doughnuts, AstraZeneca, BG Group, Jazz Pharmaceuticals and Santarus

  The Zacks Analyst Blog Highlights: Krispy Kreme Doughnuts, AstraZeneca, BG
                   Group, Jazz Pharmaceuticals and Santarus

PR Newswire

CHICAGO, July 17, 2013

CHICAGO, July 17, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Krispy Kreme Doughnuts Inc.
(NYSE:KKD-Free Report), AstraZeneca (NYSE:AZN-Free Report), BG Group
(OTC:BRGYY-Free Report), Jazz Pharmaceuticals (Nasdaq:JAZZ-Free Report) and
Santarus, Inc. (Nasdaq:SNTS-Free Report).


Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

Krispy Kreme Approves Buyback

Krispy Kreme Doughnuts Inc. (NYSE:KKD-Free Report) recently approved a new
stock repurchase program, thereby maintaining the trend of returning wealth to
its shareholders from time to time, depending on market conditions. Under this
program, the company is authorized to repurchase up to $50.0 million of its
common stock with immediate effect. As of Jul 12, 2013, Krispy Kreme had
approximately 66 million shares outstanding.

The share buyback program helps the company reduce outstanding share count,
thereby increasing earnings per share and return on equity. Apart from
bolstering shareholder value, this strategic move will also lift the
relatively undervalued share price.

The announcement pushed up the doughnut maker's stock during the trading
session on Jul 15 as it touched a new 52-week high of $20.60 and eventually
closed at $20.19.

This Winston-Salem, NC-based company completed a $20 million share repurchase
program last year. Hence, another authorization of $50 million reflects the
company's confidence in its fundamentals.

Krispy Kreme boasts a sound financial position. As of Jul 12, 2013, the
company's cash balance was nearly $55 million and unused borrowing capacity on
its revolving credit facility was approximately $31 million.

Krispy Kreme is gradually moving in a positive direction. Persistently solid
earnings, comps improvement, various strategic alliances, expansion of its
franchising business, and effective utilization of cash provided the company a
shot in the arm.

Further, the solid first-quarter 2014 results and management's increasing
faith in the company's prospects led it to raise fiscal 2014 earnings per
share guidance from the range of 53-57 cents to the range of 59-63 cents. This
revised range implies a year-over-year increase of around 26%–34%.

We believe, despite hitting its 52-week high, this Zacks Rank #2 (Buy) stock
has plenty of upside left, given its raised fiscal outlook and expected
long-term earnings growth of 25%.

AstraZeneca CFO to Leave

AstraZeneca (NYSE:AZN-Free Report) recently announced that its Chief Financial
Officer (CFO) and Executive Director, Simon Lowth, will leave the company at
the end of Oct 2013. Lowth will be joining BG Group (OTC:BRGYY-Free Report) as
CFO in November.

We remind investors that this is the second major change in AstraZeneca's
management in the last few quarters. In Aug 2012, Pascal Soriot was recruited
as the Chief Executive Officer (CEO) of the company. After taking control of
the company, Soriot has laid emphasis on bolstering AstraZeneca's pipeline.

For this purpose, the company is pursuing bolt-on acquisitions and small
deals. AstraZeneca has entered into a number of acquisitions in the last few

In addition to acquisitions, the company is targeting co-development deals.
Agreements with Karolinska Institutet (to conduct preclinical and clinical
trials for candidates targeting cardiovascular and metabolic diseases),
Moderna Therapeutics (to develop RNA therapeutics for the treatment of serious
cardiovascular, metabolic and renal diseases and cancer), NGM
Biopharmaceuticals, Inc. (to develop candidates for type II diabetes and
obesity) and BIND Therapeutics (for the development and commercialization of
cancer nanomedicine, Accurin) are efforts in this direction.

At present the company is facing several issues. The generic competition that
AstraZeneca is currently facing or expects to face for its various drugs has
put significant pressure on the company. Some of the key products like
Arimidex and Seroquel are already facing generic competition in the US, while
Nexium and Crestor generics are expected to enter the US market in 2014 and
2016, respectively.

AstraZeneca carries a Zacks Rank #4 (Sell). Companies that currently look
well-positioned include Jazz Pharmaceuticals (Nasdaq:JAZZ-Free Report) and
Santarus, Inc. (Nasdaq:SNTS-Free Report). While Jazz is a Zacks Rank #1
(Strong Buy) stock, Santarus carries a Zacks Rank #2 (Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the

Get the full Report on KKD - FREE

Get the full Report on AZN - FREE

Get the full Report on BRGYY - FREE

Get the full Report on JAZZ - FREE

Get the full Report on SNTS - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.